Company news
Edding Genor Group Holdings Limited news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Next Day Disclosure Return
October 30, 2026
Next Day Disclosure Return
October 28, 2026
Next Day Disclosure Return
October 27, 2026
Voluntary announcement - first-in-human phase i study data of GB268 presented at the esmo congress 2026
October 23, 2026
Next Day Disclosure Return
October 23, 2026
Next Day Disclosure Return
October 21, 2026
Next Day Disclosure Return
October 20, 2026
Next Day Disclosure Return
October 14, 2026
Next Day Disclosure Return
October 12, 2026
Voluntary announcement - IND approval from the NMPA for Phase II clinical trial of GB268 in colorectal cancer
October 11, 2026
Next Day Disclosure Return
October 8, 2026
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 September 2026
October 7, 2026
Next Day Disclosure Return
September 30, 2026
Next Day Disclosure Return
September 29, 2026
Next Day Disclosure Return
September 28, 2026
2026 Interim Report
September 28, 2026
EDG Announced Phase Ib/II Clinical Trial of GB268 Obtained IND Approval by NMPA
July 2, 2026
Edding Genor Group Holdings: EDG Announced EDP167 has successfully completed the first subject dosing in its Phase II clinical trial
February 8, 2026
Releases Its Interim Results for 2023
August 29, 2024
Decks
- FY2023 Earnings Presentation
Earnings · 17 slides · Apr 1, 2024
- H1 2022 Earnings Presentation
Earnings · 29 slides · August 2022
- FY2021 Earnings Presentation
Earnings · 37 slides · March 2022